FVIII activity 1 and 2 years post vector infusion in trial participants who received a therapeutic vector dose (6 × 10¹³ vg/kg of AAV5-hFVIII vs 5 × 10¹¹ to 2 × 10¹² vg/kg of SPK 8011) that maintained expression and were followed >2 years post vector. FVIII activity is reported by 1-stage assay for SPK-8011 participants and CSA in participants who received AAV5-hFVIII. Data for AAV5-hFVIII are from Pasi et al¹¹  and data for SPK-8011 are from George et al.¹⁴